Item 8.01 Other Events.

On December 6, 2019, bluebird bio, Inc. ("bluebird") issued a joint press release with Bristol-Myers Squibb Company announcing positive topline results from KarMMa, a pivotal, open-label, single arm, multicenter, Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121), the companies' lead investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple myeloma.

The full text of bluebird's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8­K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits




Exhibit
  No.                                       Description
99.1          Press release issued by bluebird bio, Inc. on December 6, 2019.
104         Cover Page Interactive Data File (embedded within the Inline XBRL document)


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses